Medshine Discovery Inc. has synthesized nitrogen-containing heterocyclic compounds acting as tyrosine-protein kinase JAK3 and Tec inhibitors.

Medshine Discovery Inc. has divulged hypoxia inducible factor 2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer.

Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).

Medshine Discovery Inc. has identified coumarin compounds reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. and Medshine Discovery Inc. have divulged novel non-fluorinated quinolones reported to be useful for the treatment of acne, bacterial infections and inflammatory disorders.

Researchers at Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified azobenzene compounds acting as endothelin-1 receptor (EDNRA; ETA) antagonists reported to be useful for the treatment of IgA nephropathy.

Medshine Discovery Inc. has divulged azaspiro compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have jointly patented pyrimidine tricyclic derivative soluble guanylate cyclase (sGC) activators. They are reported to be useful for the treatment of heart failure and hypertension.

Medshine Discovery Inc. has identified 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.